PARIS, France, May 2nd, 2023 – 06:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, today announces the Journal of Crohn’s and Colitis (JCC) publication of a piece titled “Obefazimod: a first-in-class drug for the treatment of ulcerative colitis”[1], written by global Inflammatory Bowel Disease (IBD) experts.
Abivax Reports Two-Year Efficacy and Safety Data of Obefazimod Phase 2b Maintenance Trial in Ulcerative Colitis
Abivax Receives FDA Agreement on Pediatric Development Plan with Obefazimod in IBD
Most of the net proceeds from the €49.2 million ($49.2 million) raise will go toward funding the Phase III trials of its lead candidate obefazimod (ABX464) for ulcerative colitis, as well as sustaining its operation through Q1 2023, the company announced Friday.